These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 38521132)
1. Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial. Walls GM; Mistry H; Barlesi F; Bezjak A; Pechoux CL; O'Brien M; Van Meerbeeck JP; Blackhall F; Faivre-Finn C Int J Radiat Oncol Biol Phys; 2024 Aug; 119(5):1386-1390. PubMed ID: 38521132 [TBL] [Abstract][Full Text] [Related]
2. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Faivre-Finn C; Snee M; Ashcroft L; Appel W; Barlesi F; Bhatnagar A; Bezjak A; Cardenal F; Fournel P; Harden S; Le Pechoux C; McMenemin R; Mohammed N; O'Brien M; Pantarotto J; Surmont V; Van Meerbeeck JP; Woll PJ; Lorigan P; Blackhall F; Lancet Oncol; 2017 Aug; 18(8):1116-1125. PubMed ID: 28642008 [TBL] [Abstract][Full Text] [Related]
3. Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial. Salem A; Mistry H; Hatton M; Locke I; Monnet I; Blackhall F; Faivre-Finn C JAMA Oncol; 2019 Mar; 5(3):e185335. PubMed ID: 30520977 [TBL] [Abstract][Full Text] [Related]
5. Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status. Faivre-Finn C; Falk S; Ashcroft L; Bewley M; Lorigan P; Wilson E; Groom N; Snee M; Fournel P; Cardenal F; Bezjak A; Blackhall F BMJ Open; 2016 Jan; 6(1):e009849. PubMed ID: 26792218 [TBL] [Abstract][Full Text] [Related]
6. [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer]. You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):28-34. PubMed ID: 28103970 [TBL] [Abstract][Full Text] [Related]
7. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239. Komaki R; Paulus R; Ettinger DS; Videtic GM; Bradley JD; Glisson BS; Langer CJ; Sause WT; Curran WJ; Choy H Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e531-6. PubMed ID: 22560543 [TBL] [Abstract][Full Text] [Related]
9. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Schild SE; Bonner JA; Shanahan TG; Brooks BJ; Marks RS; Geyer SM; Hillman SL; Farr GH; Tazelaar HD; Krook JE; Geoffroy FJ; Salim M; Arusell RM; Mailliard JA; Schaefer PL; Jett JR Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):943-51. PubMed ID: 15234027 [TBL] [Abstract][Full Text] [Related]
10. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342 [TBL] [Abstract][Full Text] [Related]
11. Moderately Hypofractionated Once-Daily Compared With Twice-Daily Thoracic Radiation Therapy Concurrently With Etoposide and Cisplatin in Limited-Stage Small Cell Lung Cancer: A Multicenter, Phase II, Randomized Trial. Qiu B; Li Q; Liu J; Huang Y; Pang Q; Zhu Z; Yang X; Wang B; Chen L; Fang J; Lin M; Jiang X; Guo S; Guo J; Wang D; Liu F; Chu C; Huang X; Xie C; Liu H Int J Radiat Oncol Biol Phys; 2021 Oct; 111(2):424-435. PubMed ID: 33992717 [TBL] [Abstract][Full Text] [Related]
12. Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer. Rwigema JM; Verma V; Lin L; Berman AT; Levin WP; Evans TL; Aggarwal C; Rengan R; Langer C; Cohen RB; Simone CB Cancer; 2017 Nov; 123(21):4244-4251. PubMed ID: 28678434 [TBL] [Abstract][Full Text] [Related]
13. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. Curran WJ; Paulus R; Langer CJ; Komaki R; Lee JS; Hauser S; Movsas B; Wasserman T; Rosenthal SA; Gore E; Machtay M; Sause W; Cox JD J Natl Cancer Inst; 2011 Oct; 103(19):1452-60. PubMed ID: 21903745 [TBL] [Abstract][Full Text] [Related]
14. Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation. Videtic GM; Truong PT; Dar AR; Yu EW; Stitt LW Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):709-16. PubMed ID: 14529775 [TBL] [Abstract][Full Text] [Related]
15. Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial. Colaco R; Sheikh H; Lorigan P; Blackhall F; Hulse P; Califano R; Ashcroft L; Taylor P; Thatcher N; Faivre-Finn C Lung Cancer; 2012 Apr; 76(1):72-7. PubMed ID: 22014897 [TBL] [Abstract][Full Text] [Related]
16. Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial. Sheikh H; Colaco R; Lorigan P; Blackhall F; Califano R; Ashcroft L; Taylor P; Thatcher N; Faivre-Finn C Lung Cancer; 2011 Oct; 74(1):75-9. PubMed ID: 21353720 [TBL] [Abstract][Full Text] [Related]
17. Phase 1 Dose Escalation Study of Accelerated Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Lung Cancer. Kelsey CR; Das S; Gu L; Dunphy FR; Ready NE; Marks LB Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):997-1004. PubMed ID: 26581138 [TBL] [Abstract][Full Text] [Related]
18. High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial. Yu J; Jiang L; Zhao L; Yang X; Wang X; Yang D; Zhuo M; Chen H; Huang W; Zhu Z; Zhang M; Song Y; Li Q; Ma Z; Wang Q; Qu Y; Yu R; Yu H; Zhao J; Shi A; Lancet Respir Med; 2024 Oct; 12(10):799-809. PubMed ID: 39146944 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of Radiation Therapy Treatment Plans in a Randomized Phase 2 Trial Comparing 2 Schedules of Twice-Daily Thoracic Radiation Therapy in Limited Stage Small Cell Lung Cancer. Levin N; Killingberg KT; Halvorsen TO; Danielsen S; Grønberg BH Int J Radiat Oncol Biol Phys; 2024 Oct; 120(2):332-342. PubMed ID: 38583494 [TBL] [Abstract][Full Text] [Related]
20. Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses. Hu X; Bao Y; Xu YJ; Zhu HN; Liu JS; Zhang L; Guo Y; Jin Y; Wang J; Ma HL; Xu XL; Song ZB; Tang HR; Peng F; Fang M; Kong Y; Chen MY; Dong BQ; Zhu L; Yu C; Yu XM; Hong W; Fan Y; Zhang YP; Chen PC; Zhao Q; Jiang YH; Zhou XM; Chen QX; Sun WY; Mao WM; Chen M Cancer; 2020 Feb; 126(4):840-849. PubMed ID: 31714592 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]